The disease process in Alzheimer's disease involves local inflammatory processes wherein microglia are activated and produce pro-inflammatory cytokines. Accumulations of amyloid beta-peptide promote neuroinflammation by causing oxidative stress and damage to neurons and the microglia react to that damage. In this episode I talk with John Fryer about mechanisms of neuroinflammation and new immunotherapy approaches targeting amyloid in Alzheimer's disease including the use of 'nanobodies' which are small single-domain antibodies produced in camels and adapted for research and therapeutic purposes. John was previously an investigator at the Mayo Clinic and is now Director of the Center for Accelerated Nanotherapeutics in Phoenix. Note that one's risk for Alzheimer's disease is reduced by regular exercise, heart-healthy diets, and keeping intellectually and socially engaged throughout life.

LINKS

Fryer webpage at Tgen:

Articles

https://pmc.ncbi.nlm.nih.gov/articles/PMC5565413/pdf/pnas.201701137.pdf

https://pmc.ncbi.nlm.nih.gov/articles/PMC13148177/pdf/nihms-2168146.pdf

https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70269

https://pmc.ncbi.nlm.nih.gov/articles/PMC13329261/pdf/ALZ-22-e71639.pdf

https://pmc.ncbi.nlm.nih.gov/articles/PMC6122978/pdf/JEM_20180653.pdf